MNKD earnings call for the period ending December 31, 2024.
Image source: The Motley Fool.
MannKind (MNKD -3.19%)
Q4 2024 Earnings Call
Feb 26, 2025, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good afternoon, and welcome to the MannKind Corporation fourth quarter and year-end 2024 financial results earnings call. As a reminder, this call is being recorded on February 26, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risk and uncertainty, which can cause actual risk to differ materially from these stated expectations.
For further information on the company’s risk factors, please see the 10-K report filed with the Securities and Exchange Commission this afternoon, the earnings release, and the slides prepared for this presentation. Joining us today for MannKind are chief executive officer, Michael Castagna; and chief financial officer, Chris Prentiss. I’d now like to turn the conference over to Mr. Castagna.
Please go ahead, sir.
Michael E. Castagna — Chief Executive Officer and Director
Thank you, operator, and good afternoon, everyone. Thank you for joining our call today. It’s never been a better time to be on the journey with MannKind. As I look at our future, we have five key pillars.
We have two FDA-approved products on our Technosphere platform, a strong balance sheet with double-digit growth enabling us to have flexibility in the future, and also the ability to fund our two novel pipeline opportunities with clofazimine inhalation suspension and the nintedanib DPI as I’ll talk about later in our call. Let me highlight Q4 and some of the year-end highlights from 2024. First, our endocrine business unit had record revenues with Q4 revenue of $23 million and full year at $82 million. We started this year by appointing Dominic Marasco as president of our EBU, which I’ll talk about at growth strategy in a couple slides.
